Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.7900 (-2.01%) ($7.7800 - $8.0700) on Wed. May. 1, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.98% (three month average) | RSI | 34 | Latest Price | $7.7900(-2.01%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.49% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-7%) IFRA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.49% (StdDev 4.98%) | Hourly BBV | 0 () | Intraday Trend | -2.4% | | | |
|
Resistance Level | $8.09 | 5 Day Moving Average | $7.95(-2.01%) | 10 Day Moving Average | $7.98(-2.38%) | 20 Day Moving Average | $8.09(-3.71%) | To recent high | -8.1% | To recent low | 50.1% | Market Cap | $987m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |